DISCLAIMER: This product is strictly for research use only. It is meant solely for laboratory testing and in vitro studies-not for use in or on humans or animals. All details provided on this site are for educational purposes. This item is not intended to be used as a drug, supplement, or cosmetic, and must not be misrepresented as such.
Retatrutide
Retatrutide is a next-generation investigational peptide being studied for its powerful effects on weight loss, metabolism, and overall metabolic health. It acts on three different hormone receptors (GLP-1, GIP, and glucagon), making it a triple agonist designed to help the body manage blood sugar, burn fat, and control appetite more effectively.
Variant: 10 mg
Quantity: 1
All peptides arrive in powdered form for stability.
Third-Party Verified Purity
Each batch is tested and certified to meet or exceed 99% purity standards.
Made in the USA
Produced in United States WHO/GMP and ISO 9001:2015 certified facilities.
Rigorous Quality Control
Double-tested to ensure the highest quality for the most effective research.
What is Retatrutide?
Retatrutide (LY3437943) is an investigational peptide developed by Eli Lilly that acts as a triple hormone receptor agonist, targeting GLP-1, GIP, and glucagon receptors. This next-generation compound is being studied for its powerful effects on weight loss, insulin sensitivity, and metabolic health. The unique triple-receptor mechanism may allow Retatrutide to outperform single or dual agonists like Semaglutide or Tirzepatide.
Potential Benefits Shown in Studies
- Rapid and sustained weight loss
- Reducing body fat and preserving muscle mass
- Controlling blood sugar and insulin resistance
- Decreasing appetite and food cravings
- Boosting metabolism and energy use
- Supporting liver health and fat reduction
- Improving markers of heart and metabolic function
Mechanisms of Action
Retatrutide combines three synergistic metabolic pathways:
- GLP-1 receptor activation: Lowers blood sugar, suppresses appetite, slows gastric emptying
- GIP receptor activation: Enhances insulin secretion and may protect beta cells
- Glucagon receptor activation: Increases energy expenditure and fat oxidation
This triple-agonist profile helps drive both caloric reduction and metabolic acceleration — leading to substantial fat loss and improved insulin control.
Molecular Structure of Retatrutide
Sequence
Retatrutide is a synthetic peptide with a modified sequence combining features of GLP-1, GIP, and glucagon analogues. (Exact amino acid sequence is proprietary and not publicly disclosed as of current publications.)
Molecular Properties
Retatrutide Research Highlights
In a 2023 Phase 2 trial published in The New England Journal of Medicine, participants receiving 12 mg of Retatrutide weekly lost an average of 24.2% of their body weight after 48 weeks — exceeding the average seen with Semaglutide or Tirzepatide.
In patients with type 2 diabetes, Retatrutide led to HbA1c reductions of up to 2.2% and improved fasting glucose. The effects were observed across all dosage levels.
Retatrutide is now in the TRIUMPH program, a set of global Phase 3 trials assessing its long-term safety and efficacy in obesity, cardiovascular disease, and prediabetes.
